Kite’s Yescarta Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of R/R LBCL

On March 21, 2023, Kite announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment in adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. These findings will be presented in full later this year at an upcoming scientific meeting.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Kite, the Kite logo, Yescarta, and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.
© 2017-2022 Gilead Sciences, Inc. All rights reserved.